Alexandra S Reynolds1,2, Monica L Chen1, Alexander E Merkler1, Abhinaba Chatterjee1, Iván Díaz1,3, Babak B Navi1, Hooman Kamel4. 1. Department of Neurology, Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, New York, New York, USA. 2. Department of Neurology, Columbia College of Physicians and Surgeons, New York, New York, USA. 3. Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York, USA. 4. Department of Neurology, Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, New York, New York, USA, hok9010@med.cornell.edu.
Abstract
BACKGROUND: In 2013, investigators from A Randomized Trial of Unruptured Brain Arteriovenous Malformations (AVM; ARUBA) reported that interventions to obliterate unruptured AVMs caused more morbidity and mortality than medical management. OBJECTIVE: We sought to determine whether interventions for unruptured AVM decreased after publication of ARUBA results. METHODS: We used the Nationwide Readmissions Database to assess trends in interventional AVM management in patients ≥18 years of age from 2010 through 2015. Unruptured brain AVMs were identified using International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 747.81 and excluding any patient with a diagnosis of intracranial hemorrhage. Our primary outcome was interventional AVM treatment, identified using ICD-9-CM procedure codes for surgical resection, endovascular therapy, and stereotactic radiosurgery. Join-point regression was used to assess trends in the incidence of interventional AVM management among adults from 2010 through 2015. RESULTS: There was no significant U.S. population level change in unruptured brain AVM intervention rates before versus after ARUBA (p = 0.59), with the incidence of AVM intervention ranging from 8.0 to 9.2 per 10 million U.S. residents before the trial publication to 7.7-8.3 per 10 million afterwards. CONCLUSIONS: In a nationally representative sample, we found no change in rates of interventional unruptured AVM management after publication of the ARUBA trial results.
RCT Entities:
BACKGROUND: In 2013, investigators from A Randomized Trial of Unruptured Brain Arteriovenous Malformations (AVM; ARUBA) reported that interventions to obliterate unruptured AVMs caused more morbidity and mortality than medical management. OBJECTIVE: We sought to determine whether interventions for unruptured AVM decreased after publication of ARUBA results. METHODS: We used the Nationwide Readmissions Database to assess trends in interventional AVM management in patients ≥18 years of age from 2010 through 2015. Unruptured brain AVMs were identified using International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 747.81 and excluding any patient with a diagnosis of intracranial hemorrhage. Our primary outcome was interventional AVM treatment, identified using ICD-9-CM procedure codes for surgical resection, endovascular therapy, and stereotactic radiosurgery. Join-point regression was used to assess trends in the incidence of interventional AVM management among adults from 2010 through 2015. RESULTS: There was no significant U.S. population level change in unruptured brain AVM intervention rates before versus after ARUBA (p = 0.59), with the incidence of AVM intervention ranging from 8.0 to 9.2 per 10 million U.S. residents before the trial publication to 7.7-8.3 per 10 million afterwards. CONCLUSIONS: In a nationally representative sample, we found no change in rates of interventional unruptured AVM management after publication of the ARUBA trial results.
Authors: Rustam Al-Shahi Salman; Philip M White; Carl E Counsell; Johann du Plessis; Janneke van Beijnum; Colin B Josephson; Tim Wilkinson; Catherine J Wedderburn; Zoe Chandy; E Jerome St George; Robin J Sellar; Charles P Warlow Journal: JAMA Date: 2014 Apr 23-30 Impact factor: 56.272
Authors: Catherine J Wedderburn; Janneke van Beijnum; Jo J Bhattacharya; Carl E Counsell; Vakis Papanastassiou; Vaughn Ritchie; Richard C Roberts; Robin J Sellar; Charles P Warlow; Rustam Al-Shahi Salman Journal: Lancet Neurol Date: 2008-02-01 Impact factor: 44.182
Authors: Mayank Goyal; Johanna M Ospel; Nima Kashani; Adnan H Siddiqui; Ricardo Hanel; Mohammed Almekhlafi; René Chapot Journal: Neuroradiology Date: 2020-04 Impact factor: 2.804
Authors: Brent C Morel; Blake Wittenberg; Jessa E Hoffman; David E Case; Zach Folzenlogen; Christopher Roark; Joshua Seinfeld Journal: J Pers Med Date: 2022-05-30